Breaking news

In this trial, nonhospitalized patients with symptomatic COVID-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression received a single infusion of sotrovimab at a dose of 500 mg or placebo.

In a prospective cross-sectional study, the authors determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects.

In this article, the authors provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern.

The authors analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020.

The objective of this prospective cohort study was to determine associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with COVID-19 among nursing home residents, nursing home staff, and healthcare workers.

The objective of this test negative design study was to estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).

In this article the authors aimed to quantify the risk of acute myocardial infarction and ischaemic stroke associated with COVID-19 by analysing all COVID-19 cases in Sweden.

Using a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of cerebral and portal vein thrombosis in the two weeks following a diagnosis of COVID-19 were calculated.

This study aimed to summarize the global research evidence describing the effect of COVID-19 isolation measures on the health of people living with dementia.

The authors of this study report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.

For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of cerebral venous thrombosis symptoms, or blood test results.

In this study the authors aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.

Cross-sectional case-control studies (Blue) Bell’s palsy is a rare adverse event reported in clinical trials of COVID-19 vaccines. However, no population-based study has assessed the association between the inactivated SARS-CoV-2 vaccines and Bell’s palsy. The aim of this study was… Continue Reading

Observational, retrospective study of 70 patients with AIS, including 22 subjects with evidence of acute COVID-19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020.

In this article the authors describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine.